⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

October 1, 2024

Supplemental Table 5 from Abiraterone, Olaparib, or Abiraterone + Olaparib in First-Line Metastatic Castration-Resistant Prostate Cancer with DNA Repair Defects (BRCAAway)

Maha Hussain Masha Kocherginsky Neeraj Agarwal Nabil Adra Jingsong Zhang Channing J. Paller Joel Picus Zachery R. Reichert Russell Z. Szmulewitz Scott T. Tagawa Timothy M. Kuzel Latifa A. Bazzi Stephanie Daignault‐Newton Young E. Whang Robert Dreicer Ryan D. Stephenson Matthew B. Rettig Daniel H. Shevrin Travis Gerke Arul M. Chinnaiyan Emmanuel S. Antonarakis

View at Publisher

Ask AI

Bookmark

Share

No abstract yet

We only have this paper's title and publication details.

Read it at the source→

Abstract

Supplemental Table 5. Treatment-Related AEs in Exploratory Arms.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Hussain et al. (2024) studied this question.

synapsesocial.com/papers/68e56226e2b3180350efeeb8 https://doi.org/10.1158/1078-0432.27142236

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplemental Table 1 from Abiraterone, Olaparib, or Abiraterone + Olaparib in First-Line Metastatic Castration-Resistant Prostate Cancer with DNA Repair Defects (BRCAAway)2024
2Supplemental Figure 2 from Abiraterone, Olaparib, or Abiraterone + Olaparib in First-Line Metastatic Castration-Resistant Prostate Cancer with DNA Repair Defects (BRCAAway)2024
3Supplemental Table 4 from Abiraterone, Olaparib, or Abiraterone + Olaparib in First-Line Metastatic Castration-Resistant Prostate Cancer with DNA Repair Defects (BRCAAway)2024
4Supplemental Table 6 from Abiraterone, Olaparib, or Abiraterone + Olaparib in First-Line Metastatic Castration-Resistant Prostate Cancer with DNA Repair Defects (BRCAAway)2024
5Supplemental Table 3 from Abiraterone, Olaparib, or Abiraterone + Olaparib in First-Line Metastatic Castration-Resistant Prostate Cancer with DNA Repair Defects (BRCAAway)2024

More related papers

Supplemental Figure 1 from Abiraterone, Olaparib, or Abiraterone + Olaparib in First-Line Metastatic Castration-Resistant Prostate Cancer with DNA Repair Defects (BRCAAway)2024
Data from Abiraterone, Olaparib, or Abiraterone + Olaparib in First-Line Metastatic Castration-Resistant Prostate Cancer with DNA Repair Defects (BRCAAway)2024
Overall survival from the phase 2 trial of abiraterone, olaparib, or abiraterone + olaparib in first-line metastatic castration-resistant prostate cancer (mCRPC) with DNA repair defects (BRCAAway).2026